HC Wainwright initiated coverage on shares of Avalo Therapeutics (NASDAQ:AVTX – Free Report) in a research note issued to investors on Thursday morning, Marketbeat.com reports. The brokerage issued a neutral rating on the stock.
Avalo Therapeutics Stock Performance
Avalo Therapeutics stock opened at $14.44 on Thursday. Avalo Therapeutics has a 1 year low of $3.95 and a 1 year high of $34.46. The firm’s 50 day moving average price is $9.47 and its two-hundred day moving average price is $11.26.
Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($14.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.70) by ($7.37). Equities research analysts forecast that Avalo Therapeutics will post -7.78 earnings per share for the current year.
Institutional Trading of Avalo Therapeutics
Avalo Therapeutics Company Profile
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Recommended Stories
- Five stocks we like better than Avalo Therapeutics
- How to buy stock: A step-by-step guide for beginners
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- The Significance of Brokerage Rankings in Stock Selection
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.